Impact of Newly Approved Epcolitamab on Treatment of R/R DLBCL

Tysel Phillips, M.D., Ph.D., Associate Professor, Department of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, recently Approval of subcutaneous administration of epcolitamab (Epkinly) for the treatment and impact on the field of patients with relapsed/refractory diffuse large B-cell lymphoma after two or more systemic therapies.

According to Phillips, the agent’s convenience has made its introduction into the space exciting. This could be considered an alternative to chimeric antigen receptor (CAR) T-cell therapy that could be implemented in the community.

0:08 | So I think the biggest impact is obviously that these drugs can be administered in the community and not necessarily in specialized registered CAR centers. It is therefore hoped that this drug will be in the hands of more physicians and hopefully incorporated into treatment algorithms for more patients. The biggest thing going forward is that community physicians and physicians with no experience of bispecific disease or CAR T matched common adverse events between bispecific disease with cytokine release syndrome CRS and CAR T I think it’s about adapting to some of the Or, as you know, the neurological complication Immune Cell Activation Neurological Symptoms (ICAN).

0:49 | As more doctors get used to drug therapy and to deal with some of these adverse effects, I think they will not have to see patients for this kind of treatment.

0:58 | Due to the ease of gimmicking compared to what is done with CAR T, there will be a significant increase in the number of patients receiving these treatments with specific antibodies, and CAR T probably has a larger share of the market for this patient group at this time. It will be With the involvement of local physicians, if these responses that we are seeing are sustained, who of the patients who had me in complete remission remain in remission, and how many of them are in remission? Long-term follow-up from studies has maintained persistence. And then we’re starting to treat some of these patients. Again, it will only increase the number of patients who actually have an effective and curative treatment for large cell lymphoma. The ultimate goal is to cure these patients. Because this behavior of the cancer prevents the patient from living with it. , so you need to get rid of it. Or it’s deadly.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *